Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 2, 2009, Pages 335-340

  Kilburn, Lindsay B ^a   Bonate, Peter L ^b   Blaney, Susan M ^a   McGuffey, Leticia ^a   Nuchtern, Jed G ^a   Dauser, Robert ^a   Thompson, Patrick ^a   Gibson, Brian W ^a   Berg, Stacey L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b GENZYME CORPORATION   (United States)

Author keywords

CSF; ILX651; Non human primate; Pharmacokinetics; Tasidotin

Indexed keywords

DEPSIPEPTIDE; ILK 651; TASIDOTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG TOLERABILITY; LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PRIMATE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; CARBOXYLIC ACIDS; DISEASE MODELS, ANIMAL; INJECTIONS, INTRAVENOUS; MACACA MULATTA; MALE; METABOLIC CLEARANCE RATE; OLIGOPEPTIDES;

EID: 67349213588     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0875-7     Document Type: Article

References (24)

1. F Pellegrini DR Budman 2005 Review: tubulin function, action of antitubulin drugs, and new drug development Cancer Invest 23 264 273 (Pubitemid 40770744)
2. SJ Kellie D Barbaric P Koopmans J Earl DJ Carr SS de Graaf 2002 Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing: a surrogate marker of brain penetration Cancer 94 1815 1820 (Pubitemid 34241121)
3. A Rice ML Michaelis G Georg Y Liu B Turunen KL Audus 2003 Overcoming the blood-brain barrier to taxane delivery for neurodegenerative diseases and brain tumors J Mol Neurosci 20 339 343 (Pubitemid 38146991)
4. R Bai SJ Friedman GR Pettit E Hamel 1992 Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules Biochem Pharmacol 43 2637 2645
5. MA Jordan D Walker M de Arruda T Barlozzari D Panda 1998 Suppression of microtubule dynamics by binding of cemadotin to tubulin: possible mechanism for its antitumor action Biochemistry 37 17571 17578 (Pubitemid 29013759)
6. R Bai GR Pettit E Hamel 1990 Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain Biochem Pharmacol 39 1941 1949 (Pubitemid 20187330)
7. Stephenson K, Prasad V, Weitman S, Ludena RF (2004) ILX651 disrupts microtuble assembly by two mechanisms. AACR Meeting Abstracts 1297-c
8. A Ray T Okouneva T Manna HP Miller S Schmid L Arthaud R Luduena MA Jordan L Wilson 2007 Mechanism of action of the microtubule-targeted antimitotic depsipeptide tasidotin (formerly ILX651) and its major metabolite tasidotin C-carboxylate Cancer Res 67 3767 3776 (Pubitemid 46762163)
9. C Cunningham LJ Appleman M Kirvan-Visovatti DP Ryan E Regan S Vukelja PL Bonate F Ruvuna RJ Fram A Jekunen S Weitman LA Hammond JP Eder Jr 2005 Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors Clin Cancer Res 11 7825 7833 (Pubitemid 41611627)
10. S Ebbinghaus E Rubin E Hersh LD Cranmer PL Bonate RJ Fram A Jekunen S Weitman LA Hammond 2005 A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors Clin Cancer Res 11 7807 7816 (Pubitemid 41611625)
11. DF McDermott E Hersh J Weber J Stephenson CC Cunningham S Ebbinghaus J Thompson S O'Day S Weitman LA Hammond 2005 ILX651 administered daily for five days every 3 weeks (qdx5dq3w) in patients (pts) with inoperable locally advanced or metastatic melanoma:phase II experience J Clin Oncol ASCO Annu Meet Proc 23 7556
12. AC Mita LA Hammond PL Bonate G Weiss H McCreery S Syed M Garrison QS Chu JS DeBono CB Jones S Weitman EK Rowinsky 2006 Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors Clin Cancer Res 12 5207 5215 (Pubitemid 44453350)
13. Roth S, Krumbholz R, Arthaud L, Weitman S, Stephenson K (2004) In vivo and in vitro antitumor effects of ILX651, a pentapeptide with anovel mechanism of action. AACR Meet Abstr 488
14. Roth S, Krumbholz R, Schmid S, Arthaud L, Weitman S (2006) Tasidotin HCl (ILX651): in vivo antitumor effects after intravenous or oral administration. AACR Meet Abstr 66-c
15. Zhang WE, Kolb EA (2005) ILX651 inhibits growth of pediatric sarcoma lines in vitro and in vivo. AACR Meet Abstr 808
16. JD Herrington L Di Nunno JJ Rinehart 1998 Lack of CNS penetration of docetaxel in a patient with leptomeningeal carcinomatosis Ann Pharmacother 32 611 612 (Pubitemid 28232771)
17. CL McCully FM Balis J Bacher J Phillips DG Poplack 1990 A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid Lab Anim Sci 40 520 525 (Pubitemid 20372873)
18. Council NR (1996) Guide for the care and use of laboratory animals. National Academy Press
19. Lewiston DEWA, Bonate PL et al (2004) Determination of ILX-651 (a synthetic analog of dolastatin-15) in human plasma by an LC/MS/MS method. Presented at American association of pharmaceutical scientists annual meeting M1012
20. YAe Shargel L (1999) Applied biopharmaceutics and pharmacokinetics. McGraw Hill, New York
21. V Garg W Zhang P Gidwani M Kim EA Kolb 2007 Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma Clin Cancer Res 13 5446 5454 (Pubitemid 47510372)
22. MJ Glantz H Choy CM Kearns PC Mills LU Wahlberg EG Zuhowski P Calabresi MJ Egorin 1995 Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors J Natl Cancer Inst 87 1077 1081
23. S Fellner B Bauer DS Miller M Schaffrik M Fankhanel T Spruss G Bernhardt C Graeff L Farber H Gschaidmeier A Buschauer G Fricker 2002 Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo J Clin Invest 110 1309 1318 (Pubitemid 35285757)
24. JJ Heimans JB Vermorken JG Wolbers CM Eeltink OW Meijer MJ Taphoorn JH Beijnen 1994 Paclitaxel (Taxol) concentrations in brain tumor tissue Ann Oncol 5 951 953